Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
5.65 USD | -8.13% |
|
-15.92% | +284.35% |
05-30 | FDA Grants Candel Therapeutics' CAN-3110 Orphan Drug Designation to Treat Recurrent High-Grade Glioma | MT |
05-30 | Candel Therapeutics Gets FDA's Orphan-Drug Status for Glioma Treatment | DJ |
Official Publications
No official publication found
- Stock Market
- Equities
- CADL Stock
- News Candel Therapeutics, Inc.
- Official Publications